Informed Consent for Deep Brain Stimulation (DBS) Implantation

Section 1info grid
Section 2text block
Section 3text block
Section 4list block
Section 5list block
Section 6text block
Section 7text block
Section 8text block
Section 9text block
Section 10text block
Section 11text block
Section 12text block
Section 13signature block

Informed Consent for Deep Brain Stimulation (DBS) Implantation

Patient and Surgical Information

Nature and Purpose of the Procedure

Deep Brain Stimulation (DBS) is a neurosurgical procedure in which one or two thin electrode arrays are implanted into precisely targeted brain regions responsible for abnormal movement circuits, connected by subcutaneous wires to an implantable pulse generator (IPG) neurostimulator placed under the skin of the chest wall. The system delivers continuous adjustable electrical stimulation that modulates the targeted brain circuit to suppress abnormal neurological symptoms. DBS is indicated for movement disorders (Parkinson's disease, essential tremor, dystonia) and selected psychiatric conditions (obsessive-compulsive disorder) that have not responded adequately to maximum pharmacological management. The procedure involves: (1) Preoperative stereotactic MRI target planning; (2) Frame or frameless stereotactic electrode implantation, typically performed with the patient awake (to allow real-time neurophysiological mapping and intraoperative clinical testing of stimulation effects); (3) A second surgical stage under general anesthesia to implant the IPG neurostimulator in the chest and connect the system. The DBS system requires ongoing programming by a specialized neurologist and battery replacement (via minor surgery) every 3 to 5 years, or continuous recharging if a rechargeable IPG is used.

Awake Craniotomy Disclosure

The electrode implantation stage is typically performed while the patient is awake and alert, under local anesthesia and conscious sedation. Being awake allows the surgical team to perform microelectrode recording to map the target brain region and to test stimulation effects in real time (tremor suppression, speech testing, and assessment of side effects). Although patients generally tolerate the procedure well, you may experience: awareness of skull pin placement, headframe application, and cranial drilling; transient neurological symptoms during testing; anxiety or claustrophobia during the procedure. An anesthesia team is present throughout to manage comfort and safety. You may request sedation at any time. A trial of awake sedation can be arranged preoperatively if anxiety is significant.

Material Risks and Potential Complications

Intracranial hemorrhage: bleeding in the brain from electrode insertion, occurring in approximately 1 to 3 percent; may cause permanent neurological deficit or stroke.
Stroke: thromboembolic or hemorrhagic stroke occurring in approximately 1 percent; may cause permanent weakness, speech impairment, or cognitive change.
Electrode misplacement: failure to achieve optimal anatomical targeting, requiring electrode repositioning in approximately 3 to 5 percent of implantations.
Hardware complications: electrode fracture, lead migration, connector failure, or IPG malfunction requiring surgical revision (occurring in 5 to 10 percent of patients over the device lifetime).
Infection: wound infection or hardware infection occurring in 2 to 5 percent; may require prolonged antibiotic therapy or hardware explantation.
Stimulation-related side effects: depending on target, may include speech slurring (dysarthria), involuntary movements, muscle contractions, visual disturbances, depression, impulsivity, or cognitive changes. Most are reversible with parameter adjustment; some may persist.
MRI restrictions: DBS systems require specific safety protocols for MRI scanning; not all MRI body regions are safe with DBS active. Patients must carry their device identification card and inform all imaging staff before any MRI procedure.
Death: a rare but recognized risk of any major neurosurgical procedure; risk is less than 0.5 percent in appropriately selected patients at specialist centers.

Alternatives to Deep Brain Stimulation

Continued optimal pharmacological therapy: medication dose adjustment, combination therapy (levodopa, dopamine agonists, MAO-B inhibitors in PD; propranolol, primidone in ET). DBS is considered when medications are no longer providing adequate control or their side effects limit titration.
Focused Ultrasound Thalamotomy (FUS): non-invasive ablative procedure for essential tremor and tremor-dominant PD targeting the Vim thalamus using high-intensity focused ultrasound. No hardware implantation; irreversible ablation; not available at all centers; currently unilateral only.
Stereotactic Radiosurgery (Gamma Knife Thalamotomy): radiosurgical lesion at Vim nucleus; delayed response over months; not reversible; risk of radiation necrosis; less commonly used.
Pallidotomy or Thalamotomy: surgical lesion at GPi or Vim thalamus; irreversible ablation; may be considered where DBS is not feasible.

Long-Term Device Management Obligations

DBS therapy requires lifelong engagement with a specialized DBS programming team. Following implantation, patients attend multiple programming sessions over the first 6 to 12 months to optimize stimulation parameters. Battery monitoring (for non-rechargeable IPGs) or daily recharging (for rechargeable systems) is required. Patients must present their DBS device identification card at all healthcare encounters, particularly before any MRI, diathermy, or cardiac electrophysiology procedures, as these may interfere with or damage the device. Travel through airport security is generally safe, but the DBS system should be disclosed. IPG battery replacement surgery is required every 3 to 5 years for non-rechargeable systems.

Expected Benefits

DBS has been shown to significantly reduce motor symptoms in appropriately selected patients. In Parkinson's disease, DBS reduces tremor, rigidity, and bradykinesia, reduces 'off' time, and often allows significant reduction in levodopa dosage (reducing levodopa-induced dyskinesias). Studies show 50 to 70 percent reduction in UPDRS motor scores. In essential tremor, DBS of the Vim thalamus provides greater than 70 percent tremor reduction in the majority of patients. In dystonia, improvement is often substantial but slower, occurring over months. DBS does not halt the underlying disease progression.

Right to Refuse or Withdraw Consent

You have the right to refuse this procedure or withdraw your consent at any time before the procedure begins without penalty or adverse effect on your medical care. DBS is an elective surgery and all pharmacological alternatives will remain available if you choose not to proceed.

Questions and Understanding Confirmation

I confirm that I have had the opportunity to review this consent form with my neurosurgeon and movement disorder neurologist. I understand the awake surgical procedure, the stimulation parameter programming commitment, and the MRI restrictions associated with the device. All my questions have been answered to my satisfaction.

Language Access and Interpreter Services

If English is not your primary language or if you require assistance communicating, a qualified medical interpreter is available at no cost. Please notify your care team before signing this document.

Copy of Consent Acknowledgment

I acknowledge that I have been offered a signed copy of this informed consent form and the DBS device patient information booklet for my own records.

Patient Authorization

I have been informed of the DBS implantation procedure, the expected benefits, the material risks including the risk of intracranial hemorrhage and stroke, and the available alternatives. I understand the long-term device management obligations and MRI restrictions. I consent to proceed with DBS implantation at the brain target indicated above.

Signatures and Verification

Patient / LAR Signature
Neurosurgeon Signature
Witness Signature
Date and Time
Document ID: CC-PENDING
CONSENTCOLLECT